Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C

被引:41
作者
Kees, Martin G. [1 ]
Hilpert, Justus W. [1 ]
Gnewuch, Carsten [2 ]
Kees, Frieder [3 ]
Voegeler, Stephan [1 ]
机构
[1] Charite, Dept Anesthesiol & Intens Care, D-12200 Berlin, Germany
[2] Univ Regensburg, Inst Clin Chem & Lab Med, D-93053 Regensburg, Germany
[3] Univ Regensburg, Dept Pharmacol, D-93053 Regensburg, Germany
关键词
HPLC; Pharmacokinetics; ICU; Cystatin C; Creatinine clearance; Dosing; CRITICALLY-ILL; RENAL-FUNCTION; STEADY-STATE; PHARMACOKINETICS; COCKCROFT; FORMULA; 2-HOUR; MARKER; GAULT;
D O I
10.1016/j.ijantimicag.2010.07.015
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Vancomycin (VAN) dosing requires adjustment to renal function, which is often estimated using the Cockcroft-Gault formula; however, its precision is poor in Intensive Care Unit (ICU) patients. VAN clearance (CLVan) during continuous infusion was prospectively determined in 25 ICU patients [14 male, 11 female; age range 31-82 years; body mass index (BMI) 16.5-41.5 kg/m(2); Acute Physiology and Chronic Health Evaluation (APACHE) II score at admission 8-36; creatinine clearance 25-195 mL/min] and its correlation with measured creatinine clearance (CLCrea), estimated creatinine clearance using the Cockcroft-Gault formula (CLCG) and estimated glomerular filtration rate according to Hoek's formula based on serum cystatin C (GFR(Hoek)) was investigated. The correlation between CLVan and CLCrea was very good (r(2) = 0.88), but it was rather poor with CLCG (r(2) = 0.37) and was acceptable with GFR(Hoek) (r(2) = 0.70). For VAN dose adjustments in ICU patients, determination of cystatin C may be an interesting and practical alternative to measured CLCrea, whereas the Cockcroft-Gault formula should be used with caution. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:545 / 548
页数:4
相关论文
共 26 条
[11]   A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate [J].
Hoek, FJ ;
Kemperman, FAW ;
Krediet, RT .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) :2024-2031
[12]   Assessment of renal function in recently admitted critically ill patients with normal serum creatinine [J].
Hoste, EAJ ;
Damen, J ;
Vanholder, RC ;
Lameire, NH ;
Delanghe, JR ;
Van den Hauwe, K ;
Colardyn, FA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (04) :747-753
[13]   Population pharmacokinetic parameters of vancomycin in critically ill patients [J].
Llopis-Salvia, P. ;
Jimenez-Torres, N. V. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (05) :447-454
[14]  
MARTIN JH, 2010, INTERN MED J, DOI DOI 10.1111/J.1445-5994.2010.02160.X
[15]   PHARMACOKINETICS OF VANCOMYCIN [J].
MOELLERING, RC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 14 :43-52
[16]   Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients [J].
Pea, Federico ;
Furlanut, Mario ;
Negri, Camilla ;
Pavan, Federica ;
Crapis, Massimo ;
Cristini, Francesco ;
Viale, Pierluigi .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (05) :1863-1867
[17]   Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients [J].
Poggio, ED ;
Nef, PC ;
Wang, XL ;
Greene, T ;
Van Lente, F ;
Dennis, VW ;
Hall, PM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (02) :242-252
[18]   Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients [J].
Polard, E ;
Le Bouquin, V ;
Le Corre, P ;
Kérebel, C ;
Trout, H ;
Feuillu, A ;
Le Verge, R ;
Mallédant, Y .
THERAPEUTIC DRUG MONITORING, 1999, 21 (04) :395-403
[19]   Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? [J].
Roberts, Jason A. ;
Lipman, Jeffrey ;
Blot, Stijn ;
Rello, Jordi .
CURRENT OPINION IN CRITICAL CARE, 2008, 14 (04) :390-396
[20]  
Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI [10.2146/ajhp080434, 10.1086/600877]